Andere talen Cutia Therapeutics

Aandelen

2487

KYG2606C1006

Beurs gesloten - Hong Kong S.E. Andere beurzen 10:08:03 23-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
7,28 ^HKD	-3,70%		+2,97%	-33,70%

30/04	Cutia Therapeutics' eenheid ontvangt Jiangsu certificaat voor medicijnproductie	MT
30/04	Cutia Therapeutics dient een NDA in voor de behandeling van alopecia androgenetica; aandelen stijgen met 6%.	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Cutia Therapeutics' Unit Receives Jiangsu Drug Manufacturing Certificate	30/04
Cutia Therapeutics Submits NDA for Androgenetic Alopecia Treatment Spray; Shares Jump 6%	30/04
Cutia Therapeutics Submits New Drug Application for Cu-40102 (Topical Finasteride Spray) in Hong Kong, PRC	30/04
Cutia Therapeutics Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Cutia Therapeutics' Atopic Dermatitis Drug's IND Application Accepted by China's NMPA	27/03
Cutia Therapeutics Announces the Investigational New Drug Application of CU-10101 (Topical Novel Small Molecule Agent) for the Treatment of Mild to Moderate Atopic Dermatitis Accepted by the Center for Drug Evaluation of the National Medical Products Administration	26/03
Cutia Therapeutics Included in Two FTSE Indices	18/03
Cutia Therapeutics Announces Completion of Phase I Clinical Trial of CU-20401	27/02
Cutia Therapeutics Included in Hang Seng Family of Indexes	20/02
Cutia's Phase 3 Clinical Trial for Analgesic Cream Reaches Primary Endpoint; Shares Surge 12%	31/01
China Accepts Cutia Therapeutics's New Drug Application for Alopecia Treatment; Shares Surge 13%	31/01
Cutia Therapeutics Announces New Drug Application for CU-40102 (Topical Finasteride Spray) Accepted by the National Medical Products Administration	30/01
Cutia Therapeutics Doses First Patient for Anti-Obesity Injectable	03/01
Cutia Therapeutics Announces First Patient Enrollment in the Phase II Clinical Trial of CU-20401	02/01
Cutia Therapeutics Publishes Results of Phase 3 Trial for Alopecia, Acne Treatments in China	11/12
Cutia Therapeutics Announces Results of Phase III Clinical Trials of CU-40102 (Topical Finasteride Spray) and CU-10201 (Topical 4% Minocycline Foam) in the People's Republic of China	11/12
Certain Ordinary Shares of Cutia Therapeutics are subject to a Lock-Up Agreement Ending on 11-DEC-2023.	11/12
Cutia Therapeutics' Completes Data Collection for Obesity Drug Phase 1 Trial	27/11
Cutia Therapeutics Announces Phase I Clinical Trial of Cu-20401 Abdominal Adipose Accumulation Completes Database Lock	27/11
Cutia Therapeutics Posts 595% Revenue Growth in Q3	06/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Cutia Therapeutics

Aandelen

2487

KYG2606C1006

Andere talen

Filters